Skip to main content
. 2018 Feb;13(1):55–64. doi: 10.2174/1574884713666180518102514

Fig. (4).

Fig. (4)

a) Proportion of patients with serum cytokine levels above the lower limit of quantification (LLOQ) after blinatumomab infusion start. Number of patients per first dose level: <5 µg/m2/day, n=9; 5 µg/m2/day, n=35; 15 µg/m2/day, n=18; 30 µg/m2/day, n=7; 60 µg/m2/day, n=15; 90 µg/m2/day, n=4. b) Cytokine Cmax (mean SD) in the first week of treatment as a function of blinatumomab dose. Number of patients per first dose level: <5 µg/m2/day, n=9; 5 µg/m2/day, n=35; 15 µg/m2/day, n=18; 30 µg/m2/day, n=7; 60 µg/m2/day, n=15; 90 µg/m2/day, n=4. Data below LLOQ were included as such into the analysis; data below LOD were set at 10 pg/mL (ie, ½LOD). c) Cytokine profiles after continuous IV blinatumomab doses of 60 µg/m2/day throughout treatment (n=9); elevation of cytokines was transient and declined quickly during infusion. d) Cytokine time profiles after stepwise blinatumomab dosing of 5‒15‒60 µg/m2/day (n=21); elevation of cytokines was transient and did not increase with increasing dose. Cmax observed peak concentrations, IFN interferon, IL interleukin, LLOQ lower limit of quantitation, TNF tumor necrosis factor.